The Susan G. Komen Breast Cancer Foundation, INC. DBA Susan G. Komen

Based in TX

🤖

AI Overview

With $2.5M in lobbying spend across 32 quarterly filings, The Susan G. Komen Breast Cancer Foundation, INC. DBA Susan G. Komen is a significant lobbying presence. Their lobbying covers 6 issue areas. Active from 2018 to 2025.

$2.5M

Total Spend

Years Active

Firms Hired

Lobbyists Deployed

Issues Lobbied

Spending Trend

View as table

Year	Lobbying Spend
2018	$320K
2019	$330K
2020	$230K
2021	$250K
2022	$270K
2023	$300K
2024	$310K
2025	$490K

Issues Lobbied

Health Issues Budget/Appropriations Insurance Medicare/Medicaid Defense Government Issues

Lobbying Firms

The Susan G. Komen Breast Cancer Foundation, INC. DBA Susan G. Komen

Lobbyists

Molly Guthrie Aracely Panameno Valerie Nauman Nelson

Government Agencies Targeted

These are the government entities that The Susan G. Komen Breast Cancer Foundation, INC. DBA Susan G. Komen disclosed contacting in their lobbying filings.

Centers For Disease Control & Prevention (CDC)Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)HOUSE OF REPRESENTATIVESNatl Institutes of Health (NIH)SENATEInternal Revenue Service (IRS)White House OfficeLabor, Dept of (DOL)Treasury, Dept ofOffice of Management & Budget (OMB)Office of Science & Technology Policy (OSTP)Office of Personnel Management (OPM)Vice President of the U.S.Agency for Healthcare Research & Quality (AHRQ)Consumer Financial Protection Bureau (CFPB)

View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Budget/Appropriations, Insurance, Medicare/Medicaid, Defense and 1 more

H.R.1409, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients.

H.R.930/S.497, Lymphe

H.R.1625 - Vehicle for Consolidated Appropriations Act 2018 - issues related to cancer prevention, screening and research funding.

FY2019 Labor, Health and Human Services and Education Appropriation

H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment;

H.R.1676/S.693, Palliative Care and Hospice Educatio

H.R.1409, Cancer Drug Parity Act of 2017, advocate for equitable coverage of cancer therapies;

H.R.2999, Patients Access to Treatment Act, advocate for access to cancer therapies;

H.R.4978, Chronic

FY2019 Labor, Health and Human Services and Education Appropriations Bill - issues related to cancer prevention, screening and research funding.